Related Experiment Videos
[Future molecules in heart failure]
L Hittinger1, M E Lopes, J Y Tabet
1Fédération des services de Cardiologie et service de Médecíne Nucléaire, INSERM U400 et Centre de Recherches Chirurgicales, Hôpital Henri Mondor, Créteil. luc.hittinger@hmn.ap-hop-paris.fr
Presse Medicale (Paris, France : 1983)
|February 6, 2002
Summary
Heart failure (HF) management is evolving with new strategies targeting neurohormone and immune systems. Personalized treatment plans based on patient profiling will optimize future HF care.
Area of Science:
- Cardiology
- Pharmacology
- Biomedical Science
Context:
- Heart failure (HF) management has advanced significantly.
- Current treatments focus on congestion and neurohormone inhibition.
- New therapeutic avenues are emerging based on novel physiological concepts.
Purpose:
- To explore future therapeutic strategies for heart failure.
- To identify principles for optimizing HF treatment personalization.
- To discuss the role of new diagnostic and therapeutic approaches.
Summary:
- Future HF management may involve blocking vasoconstrictor systems and stimulating vasodilator/natriuretic systems.
- Modulating cardiac remodelling, immune/inflammatory responses, contractility, and arrhythmias are potential strategies.
- Personalized medicine, using advanced diagnostics and patient stratification, is key to future HF treatment.
Impact:
- Predicting which novel strategies will improve HF prognosis requires further large-scale randomized studies.
- Optimizing treatment involves measuring hormone levels (e.g., B-type natriuretic peptide) and using advanced imaging.
- Classifying patients by etiology, disease profile, and genetic factors will enable tailored HF therapies.